Loan Loss Reserves / Non-Performing Loans (Annual)

Loan Loss Reserves / Non-Performing Loans: Allowance for bad loans as a portion of total loans made. Calculated as: Loan Loss Reserves / Non-Performing Loans

X4 Pharmaceuticals, Inc. (XFOR) Loan Loss Reserves / Non-Performing Loans data is not available.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$35.11M
Net Income	$-79.20M
Cost of Goods Sold	$5.76M
Gross Profit	$29.36M
Operating Expenses	$122.00M
Operating Income	$-86.88M
Non-Operating Income/Expense	$7.72M
Pre-Tax Income	$-79.16M
Normalized Pre-Tax Income	$-79.16M
Income after Taxes	$-79.20M
Income from Continuous Operations	$-79.20M
Consolidated Net Income/Loss	$-79.20M
Normalized Income after Taxes	$-79.20M
EBIT	$-86.88M
EBITDA	$-85.61M
Weighted-Average Shares Outstanding (Basic)	42.29M
Weighted-Average Shares Outstanding (Diluted)	42.29M
Earnings per Share (EPS) (Basic)	$-1.87
Earnings per Share (EPS) (Diluted)	$-1.87
Balance Sheet Financials
Current Assets	$261.58M
Property, Plant, and Equipment	$0.18M
Long-Term Assets	$28.88M
Total Assets	$290.46M
Current Liabilities	$25.76M
Long-Term Debt	$76.29M
Long-Term Liabilities	$78.41M
Total Liabilities	$104.17M
Common Equity	$186.29M
Tangible Shareholders Equity	$159.69M
Shareholders Equity	$186.29M
Common Shares Outstanding	90.91M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-85.62M
Cash Flow from Investing Activities	$8.15M
Cash Flow from Financial Activities	$238.63M
Beginning Cash	$56.48M
End Cash	$217.85M
Increase/Decrease in Cash	$161.38M
Stock-Based Compensation	$4.30M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	10.16
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.29
Debt to Equity Ratio	0.41
Gross Margin	83.60%
Operating Margin	-247.44%
EBIT Margin	-247.44%
EBITDA Margin	-243.80%
Pre-Tax Profit Margin	-225.44%
Profit Margin	-225.55%
Free Cash Flow	$-85.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	1.29
Receiveable Turnover	61.28
Days Sales in Receivables	5.96
Return on Equity	-42.51%
Return on Tangible Equity	-49.60%
Return on Assets	-27.27%
Return on Investments	-30.16%
Book Value Per Share	$2.05
Free Cash Flow per Share	$-2.02
Operating Cash Flow per Share	$-2.02

Data from Zacks Investment Research, Inc.